IC
ENVB icon

Ikarian Capital’s Enveric Biosciences ENVB Stock Holding History

Ikarian Capital’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+100,002
New +$240K 0.01% 144
2022
Q3 		– Sell
-25
Closed -$48K – 126
2022
Q2 		$48K Sell
25
-22
-47% -$46.8K 0.01% 135
2022
Q1 		$141K Buy
47
+3
+7% +$13.3K 0.02% 175
2021
Q4 		$372K Buy
+44
New +$618K 0.06% 143

Other funds holding ENVB

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ikarian Capital's ENVB Position: Q2 2026 in Review

Ikarian Capital opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 100,002 shares worth $138K. The stake represents 0.01% of the portfolio and ranks #144 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in ENVB as recently as Q2 2022.

Ikarian Capital first reported a position in ENVB in Q4 2021 and has held it in 4 quarters since. The position peaked at $372K in Q4 2021. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • Ikarian Capital held 100,002 shares of Enveric Biosciences worth $138K as of Q2 2026.
  • Enveric Biosciences was a new Ikarian Capital position in Q2 2026.
  • Enveric Biosciences made up 0.01% of Ikarian Capital's portfolio in Q2 2026, its #144 holding.
  • Ikarian Capital first reported a position in Enveric Biosciences in Q4 2021 and has held it in 4 quarters since.
  • Ikarian Capital's Enveric Biosciences position peaked at $372K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.